Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

J Michael Gaziano, Anthony H Cincotta, Christopher M O'Connor, Michael Ezrokhi, Dean Rutty, Z J Ma, Richard E Scranton, J Michael Gaziano, Anthony H Cincotta, Christopher M O'Connor, Michael Ezrokhi, Dean Rutty, Z J Ma, Richard E Scranton

Abstract

Objective: Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy for type 2 diabetes.

Research design and methods: A total of 3,095 patients with type 2 diabetes were randomized 2:1 to bromocriptine-QR or placebo in conjunction with the patient's usual diabetes therapy (diet controlled only or up to two antidiabetes medications, including insulin). The all-cause-safety end point was the occurrence of any serious adverse event (SAE), with a hazard ratio (HR) noninferiority margin of 1.5. In a prespecified analysis, the frequency of cardiovascular disease (CVD) events defined as a composite of myocardial infarction, stroke, coronary revascularization, and hospitalization for angina or congestive heart failure was evaluated using modified intent-to-treat analysis (clinicaltrials.gov, NCT00377676).

Results: In the bromocriptine-QR group, 176 (8.6%) people reported SAEs compared with 98 (9.6%) in the placebo group (HR 1.02 [96% one-sided CI 1.27]). Fewer people reported a CVD end point in the bromocriptine-QR group versus the placebo group (37 [1.8%] vs. 32 [3.2%], respecively) (HR 0.60 [95% two-sided CI 0.35-0.96]). Nausea was the most commonly reported adverse event in the bromocriptine-QR group.

Conclusions: The frequency of SAEs was comparable between the treatment arms. Compared with patients in the placebo arm, fewer patients taking bromocriptine-QR experienced a cardiovascular end point.

Figures

Figure 1
Figure 1
Kaplan-Meier curve of the occurrence of the prespecified composite cardiovascular end point among patients randomized to bromocriptine-QR or placebo. The composite cardiovascular end point consisted of the time to first myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization for congestive heart failure that occurred after randomization. All cardiovascular events were independently adjudicated. The hazard ratio of bromocriptine-QR versus placebo for the occurrence of the composite cardiovascular end point was 0.60 (95% CI 0.37–0.96). The effect of treatment was estimated from the unadjusted Cox proportional-hazard model that used all the available data.

References

    1. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H: The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28: 2130–2135
    1. Diabetes Facts and Figures. World Health Ogranization. Available from . Accessed
    1. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471
    1. Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand A, Tisell A, Melander A: Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558–560
    1. Walker AM, McAfee AT, Koro C: Studies of diabetes, thiazolidinediones, and coronary heart disease. Pharmacoepidemiol Drug Saf 2007; 16: 1313–1314
    1. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256–263
    1. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244–2248
    1. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis. N Engl J Med 2007; 357: 28–38
    1. Skyler JS: PROactive: A sad tale of inappropiate analysis and unjustified interpretation. Clinical Diabetes 2006; 24: 63–65
    1. Dluhy RG, McMahon GT: Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358: 2630–2633
    1. Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A: A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo. BMC Endocr Disord 2007; 7: 3.
    1. Luo S, Liang Y, Cincotta AH: Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999; 69: 160–166
    1. Luo S, Luo J, Meier AH, Cincotta AH: Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport 1997; 8: 3495–3499
    1. Cincotta A: Hypothalamic Role in the Insulin Resistance Syndrome. In Reistance and Insulin Resistance Syndrome. Hansen B, Shaffrir E. Eds. London, Taylor and Francis, 2002, p. 271–312
    1. Monti JM, Monti D: The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007; 11: 113–133
    1. Cincotta AH, Meier AH, Cincotta M, Jr: Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8: 1683–1707
    1. Cincotta AH, Meier AH: Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19: 667–670
    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus (Position Statement). Diabetes Care 2004; 27(Suppl. 1): 5–10
    1. American Diabetes Association. Standards of Medical Care in Diabetes (Position Statement). Diabetes Care 2004; 27(Suppl. 1): 15–35
    1. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. American Diabetes Association, American College of Cardiology Foundation, American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: 298–304
    1. Grassi G: Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res 2006; 29: 839–847
    1. Chiodini I, Adda G, Scillitani A, Coletti F, Morelli V, Di Lembo S, Epaminonda P, Masserini B, Beck-Peccoz P, Orsi E, Ambrosi B, Arosio M: Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 2007; 30: 83–88
    1. Grassi G: Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; 16: 1979–1987
    1. O'Keefe JH, Bell DS: Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899–904
    1. Sjöholm A, Nyström T: Endothelial inflammation in insulin resistance. Lancet 2005; 365: 610–612

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren